Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews
Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews
$599.00
Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.
Author: Datamonitor Healthcare
Publisher: Biomedtracker
- Highlights
- Description
Highlights
- “ …over time adherence is going to be an issue, and actually there are some people that have a lot of access issues too because we are filling patient assistance forms for that
drug quite often. ” - “…given in lupus there is really only four or five drugs that are ‘approved’, of which include glucocorticoids and aspirin, and hydroxychloroquine, it is just crazy. We are in a field where we use mostly off-label drugs, so again any data that would help drive the use of anything, whether it is on label or off, it would be helpful”
Overview
Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE. The specific drugs discussed include anifrolumab [AZN], atacicept [MKGAY], Benlysta / belimumab [GSK], Benlysta SC [GSK], Lupuzor / rigerimod, Luveniq / voclosporin, Orencia / abatacept [BMY], Rituxan / rituximab [RHHBF] and Xeljanz/Xeljanz XR / tofacitinib [PFE]. The two interviews were combined into a single report.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the